Synbiotic Supplement
DrugOther names: NOBEL (NBL) Probiotic Optima
NCT Number: NCT03455192
The aim of this study is to evaluate the efficacy of oral administration of synbiotic tablets on the clinical parameters and the levels of selected inflammatory mediators in gingival crevicular fluid (GCF) in smokers and non-smokers with gingivitis.
This study designed as a double-blind randomized placebo-controlled clinical trial.
Looking for future studies?
Notify Me18 year–30 year
All sexes
Interventional
Not applicable
Some patients like smokers have ongoing host response even after bacterial plaque removal achieved. Therefore efforts to develop effective treatment approaches remain an important objective in the treatment of gingivitis to prevent periodontitis especially in patients at high risk for developing periodontitis as smokers.
Smoking is a major risk factor for the incidence and the progression of periodontal diseases. The increased periodontal disease susceptibility in smokers is predominantly caused by changes in inflammatory and immune responses. Cigarette smoking also influences the amount and the composition of subgingival plaque. Smokers have higher numbers of pathogens in their resident biofilm and display an ongoing host response even after biofilm removal. Different approaches were explored to reduce the negative effects of smoking on the outcomes of periodontal therapy Synbiotic were defined as a mixture of probiotics and prebiotics that beneficially affects the host by improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract, by selectively stimulating the growth and/or by activating the metabolism of one or a limited number of health-promoting bacteria, and thus improving host welfare. Also in some cases, this may lead to a competitive advantage for the probiotics among with other bacteria.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: NOBEL (NBL) Probiotic Optima
Time frame: baseline, 1st and 2nd months
GCF samples were collected with paper strips and IL-6 levels of GCF were measured using commercial kits by using ELISA method
Time frame: baseline, 1st and 2nd months
GCF samples were collected with paper strips and IL-8 levels of GCF were measured using commercial kits by using ELISA method
Time frame: baseline, 1st and 2nd months
GCF samples were collected with paper strips and IL-10 levels of GCF were measured using commercial kits by using ELISA method
Time frame: baseline, 1st and 2nd months
Clinical parameter
Time frame: baseline, 1st and 2nd months
Clinical parameter
Time frame: baseline, 1st and 2nd months
Clinical parameter
Kırıkkale University
Other
The Effect of Synbiotic Tablet Usage on the Clinical and Biochemical Parameters in Smokers and Nonsmokers With Gingivitis: A Randomized Placebo-Controlled Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07366398
Bronchial Diseases, Bronchiolitis
Giza, Egypt
View Trial DetailsNCT07355517
Behavior, Bronchial Diseases
Irbid, Irbid Governorate, Jordan
View Trial DetailsNCT06888440
Bronchial Diseases, Bronchiolitis
Adana, Turkey (Türkiye)
View Trial DetailsNCT05919134
Bronchial Diseases, Bronchiolitis
Moscow, Russia
View Trial Details